Urinary Tract Infection Treatment Market
Urinary Tract Infection Treatment Market Analysis by Drug Class (Penicillin and Combinations, Quinolones, Cephalosporin, Aminoglycoside Antibiotics, Sulphonamides), by Indication (Complicated UTI, Uncomplicated UTI), by Distribution Channel & Regional Forecast 2021 to 2031
Analysis of Urinary Tract Infection Treatment market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Urinary Tract Infection Treatment Market Outlook (2021 to 2031)
The global urinary tract infection treatment market was valued at US$ 10.5 Bn in 2021, and is expected to increase at a CAGR of 2.1% to reach US$ 12.9 Bn by 2031.
| Data Points | Market Insights |
|---|---|
| Urinary Tract Infection Treatment Market Size (2020) | US$ 10.3 Bn |
| Forecasted Market Value (2031) | US$ 12.9 Bn |
| Global Market Growth Rate (2021 to 2031) | 2.1% |
| Share of Top 5 Countries | 50.8% |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Urinary Tract Infection Treatment Demand Analysis (2016 to 2020) Compared to Market Forecasts (2021 to 2031)
As per industry analysis by Fact.MR, a market research and competitive intelligence provider, sales of urinary tract infection treatment solutions and devices increased at a CAGR of 1.5% from 2016 to 2020.
Most pharmaceutical companies are developing antibiotics with more than one API to combat multi-drug resistant bacteria and broaden the activity spectrum of drugs. Many companies are also focusing on new drug development for uncontrolled UTI infection. Combination of products is accepted widely among physicians across the globe, and is expected to boost UTI treatment market growth over the forecast period.
Furthermore, FDA approval for new dosage forms of existing drugs is another factor that is expected to fuel development of the urinary tract infection therapeutics market over the forecast period. Also, herbal medicines for UTI treatment are gaining popularity across regions.
- In November 2020, Allergan announced FDA acceptance of Supplemental New Drug Indication for Avycaz for the treatment of patients with complicated Urinary Tract Infections (cUTI) and complicated Intra-abdominal Infections (cIAI).
Fact.MR projects the global urinary tract infection treatment market to expand at a moderate CAGR of 2.1% through 2031.
What Does the Future of UTI Infection Medicine Manufacturers Look Like?
Rising prevalence of urinary tract infections such as bladder infection, kidney infection or urethra infection, etc., and rising cases of uncomplicated urinary tract infection, are expected to boost demand for Urinary Tract Infection (UTI) treatment. Unhealthy lifestyles and high consumption of alcohol trigger chronic kidney diseases such as renal failure and bladder cancer, and this is driving kidney infection treatment demand.
Also, physicians’ preference for antibiotics for any kind of urinary tract infection is driving the antibiotics market. Collaboration of major players with research institutes are complimenting market growth by giving more treatment options for UTI treatment.
Beside antibiotics as the first line treatment for urinary tract infection, patients are looking for surgery and stimulation therapy for fast recovery. This creates demand for alternative therapies for UTI, which include a set of healthcare and medical systems and practices and products that are usually not considered to be the part of mainstream medicines, such as taking natural and herbal medicines for UTI.
Rising hospitalization rates for UTI, increasing geriatric population, and growing drug resistance are driving the interstitial cystitis market, which basically includes treatment for the chronic conditions called interstitial cystitis, and causes pain due to bladder pressure, and sometimes pelvic pain.
Driven by this, the global UTI infection medicine market is expected to rise at 2.1% CAGR through 2031.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Which Factors are Restraining Demand for Urinary Tract Infection Treatment?
Adverse effects of antibiotics are expected to hamper the urinary tract infection therapeutics market growth in the years ahead. UTI is treated with a vast range of antibiotics. However, these antibiotics have one or more adverse effects such as tendon problems, muscle weakness, allergic reactions, central nervous system-related problems, etc.
These problems can be more serious in the geriatric population, pregnant women, and children where the prevalence of UTI is higher. Additionally, continuous mutation of bacteria for existing drugs also declines market growth for UTI infection medicines to some extent for urinary tract infection treatment.
Country-wise Insights
Why is the U.S. a Leading Market for Urinary Tract Infection Treatment?
“Developed Medical Infra Driving UTI Infection Medication Sales”
The U.S. accounted for 91.4% of the North America urinary tract infection treatment market in 2021, owing to the development of many treatment facilities and rising investments in the healthcare sector. Moreover, increased rate of approvals by the U.S FDA has led to higher product penetration, making the U.S a high revenue generating country for medicines for UTI pain.
- For instance, in January 2020, Merck announced U.S. FDA approval of its drug DIFICID (fidaxomicin), which is used for the treatment of Clostridioides difficile bacteria in the pediatric population and older children.
Also, a good reimbursement scenario and rise in awareness regarding UTIs will offer lucrative opportunities for UTI treatment providers in the country.
Which Country is Leading Market UTI Market Growth in Europe?
“Germany Leading Bladder Infection Medication Demand Growth”
Germany accounted for 22.6% market share in the Europe medicines for UTI pain and treatment in 2021. Factors such as increase in geriatric population, presence of research & development programs, and high-class healthcare infrastructure are boosting demand in the urinary cystitis management market in Germany.
What’s Compelling UTI Market Players to Focus on China?
“UTI Pain Relief Medication Highly Sought-after in the Country”
China accounted for 68.9% of the East Asia market for bladder infection medications in 2021, owing to factors such as major manufacturing expansion in the country and high production capacity for antibiotic drugs.
High outsourcing potential and cost-effective production capacity for antibiotics are generating high revenue share for urinary tract infection treatment providers in China.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
Which Drug Class is Lending Traction to Market Expansion?
“Demand High for Quinolones as a Bladder Infection Medication”
By drug class, quinolones held a high share of 45.7% in 2021. Quinolones are broadly active against most Gram-negative and Gram-positive organisms, so that multi-drug resistance is avoided in the treatment of urinary tract infection.
These drugs have the capability to improve quality of life and combat symptoms with high therapeutic effect. These lifesaving advantages of quinolones make them the most lucrative and highly adopted products across regions.
Why Complicated UTI Will Give Market Players Great Growth Potential?
“cUTI Treatment to Substantially Contribute to Market Expansion”
Demand for complicated UTI treatment is expected to rise at 2.7% CAGR over the forecast period. Urinary tract infection is one of the most common infectious disease caused by bacteria. Complicated urinary tract infection can affect anyone, irrespective of gender or age group, and is mostly related to either structural or functional abnormalities in the urinary tract.
Development of multidrug-resistance bacteria is more common in cUTI, and there has been an increase in the number of multidrug-resistance bacteria, due to which, cUTI cases are increasing across the globe.
Competitive Landscape
Companies such as Pfizer and GSK, operating in the urinary tract infection treatment market, are actively entering into partnerships and collaborations, and sometimes even divestiture of some of their business divisions to maintain a relative position in the market.
- Pfizer Inc. announced the completion of a transaction to spin off its Upjohn business and combine it with Mylan N.V. to form Viatris Inc in November 2020.
- In January 2019, GSK announced that it completed the acquisition of Tesaro for approximately US$ 5.1 Bn.
Urinary Tract Infection Treatment Report Scope
| Attributes | Details |
|---|---|
| Forecast Period | 2021 to 2031 |
| Historical Data Available for | 2016 to 2020 |
| Market Analysis | USD Billion for Value |
| Key Countries Covered | U.S., Canada, Germany, U.K., France, Italy, Spain, BENELUX, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa |
| Key Market Segments Covered | Drug class, Indication, Distribution Channel, Region |
| Key Companies Profiled | Bayer AG; GlaxoSmithKline Pharmaceuticals Ltd.; Pfizer; Allergan Plc; Almirall SA; Bristol-Myers Squibb; Merck & Co., Inc. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
Urinary Tract Infection Treatment Industry Survey by Category
-
By Drug Class:
- Penicillin and Combinations
- Amoxicillin
- Amoxicillin and Clavulanate
- Potassium
- Others
- Quinolones
- Ciprofloxaxin
- Levofloxaxin
- Nalidixic acid
- Norfloxacin
- Others
- Cephalosporin
- Ceftriaxone
- Cefuroxime
- Cefixime
- Cephalexin
- Aminoglycoside Antibiotics
- Amikacin
- Gentamicin
- Sulphonamides (Sulfamethoxazole +Trimethoprim)
- Azoles and Amphotericin B
- Tetracycline (Doxycycline)
- Nirtofurans (Nitrofurantoin)
- Other
- Penicillin and Combinations
-
By Indication:
- Complicated UTI
- Uncomplicated UTI
-
By Distribution Channel:
- Hospital Pharmacies
- Gynecology and Urology Clinics
- Drug Stores
- Retail Pharmacies
- Online Drug Stores
-
By Region:
- North America Urinary Tract Infection Treatment Market
- Latin America Urinary Tract Infection Treatment Market
- Europe Urinary Tract Infection Treatment Market
- East Asia Urinary Tract Infection Treatment Market
- South Asia Urinary Tract Infection Treatment Market
- Oceania Urinary Tract Infection Treatment Market
- Middle East and Africa (MEA) Urinary Tract Infection Treatment Market
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Market Background
- 6. Global Market Demand (in Value or Size in US$ Mn) Analysis 2016 to 2020 and Forecast, 2021 to 2031
- 7. Global Market Analysis 2016 to 2020 and Forecast 2021 to 2031, by Drug Class
- 7.1. Penicillin and Combinations
- 7.1.1. Amoxicillin
- 7.1.2. Amoxicillin + Clavulanate Potassium
- 7.1.3. Others
- 7.2. Diagnostic catheters
- 7.2.1. Ciprofloxaxin
- 7.2.2. Levofloxacin
- 7.2.3. Nalidixic acid
- 7.2.4. Norfloxacin
- 7.2.5. Others
- 7.3. Cephalosporin
- 7.3.1. Ceftriaxone
- 7.3.2. Cefuroxime
- 7.3.3. Cefixime
- 7.3.4. Cephalexin
- 7.4. Aminoglycoside Antibiotics
- 7.4.1. Amikacin
- 7.4.2. Gentamicin
- 7.5. Sulphonamides (Sulfamethoxazole + Trimethoprim)
- 7.6. Azoles and Amphotericin B
- 7.7. Tetracycline (Doxycycline)
- 7.8. Nirtofurans (Nitrofurantoin)
- 7.9. Others
- 7.1. Penicillin and Combinations
- 8. Global Market Analysis 2016 to 2020 and Forecast 2021 to 2031, by Indication
- 8.1. Complicated UTIs
- 8.2. Uncomplicated UTIs
- 9. Global Market Analysis 2016 to 2020 and Forecast 2021 to 2031, by Distribution Channel
- 9.1. Hospitals Pharmacies
- 9.2. Gynaecology and Urology Clinics
- 9.3. Drug store
- 9.4. Retail Pharmacies
- 9.5. Online drug stores
- 10. Global Market Analysis 2016 to 2020 and Forecast 2021 to 2031, by Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Europe
- 10.4. South Asia
- 10.5. East Asia
- 10.6. Oceania
- 10.7. Middle East and Africa (MEA)
- 11. North America Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 12. Latin America Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 13. Europe Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 14. South Asia Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 15. East Asia Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 16. Oceania Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 17. Middle East and Africa Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 18. Key and Emerging Countries Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 19. Competition Analysis
- 19.1. Merck & Co., Inc.
- 19.2. Bayer AG
- 19.3. GlaxoSmithKline Pharmaceuticals Ltd.
- 19.4. Pfizer
- 19.5. Allergan Plc
- 19.6. Almirall SA
- 19.7. Bristol-Myers Squibb
- 20. Assumptions and Acronyms Used
- 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01A: Global Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 01B: Global Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 02: Global Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 03: Global Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 04: Global Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Region
Table 05: North America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 06A: North America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 06B: North America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 07: North America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 08: North America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 09: Latin America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 11: Latin America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 12: Latin America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 13: Europe Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 14A: Europe Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 14B: Europe Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 15: Europe Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 16: Europe Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 17: South Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 19: South Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 20: South Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 21A: East Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 21B: East Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 22: East Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 23: East Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 24: Oceania Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 25A: Oceania Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 25B: Oceania Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 26: Oceania Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 27: Oceania Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 28: MEA Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 29A: MEA Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 29B: MEA Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Class
Table 30: MEA Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Indication
Table 31: MEA Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Size (US$ Mn) Analysis, 2016 to 2020
Figure 02: Global Market Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 03: Global Market Absolute $ Opportunity, 2021 to 2031
Figure 04: Global Market Analysis by Drug Class to 2021 & 2031
Figure 05: Global Market Y-o-Y Growth Projections by Drug Class, 2021 to 2031
Figure 06: Global Market Analysis by Drug Class to 2021 & 2031
Figure 07: Global Market Analysis by Indication to 2021 & 2031
Figure 08: Global Market Y-o-Y Growth Projections by Indication, 2021 to 2031
Figure 09: Global Market Analysis by Indication to 2021 & 2031
Figure 10: Global Market Analysis by Distribution Channel to 2021 & 2031
Figure 11: Global Market Y-o-Y Growth Projections by Distribution Channel, 2021 to 2031
Figure 12: Global Market Analysis by Distribution Channel to 2021 & 2031
Figure 13: Global Market Analysis by Region to 2021 & 2031
Figure 14: Global Market Y-o-Y Growth Projections by Region, 2021 to 2031
Figure 15: Global Market Analysis by Region to 2021 & 2031
Figure 16: North America Market Size (US$ Mn) Analysis, 2016 to 2020
Figure 17: North America Market Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 18: North America Market Analysis by Country to 2021 & 2031
Figure 19: North America Market Analysis by Drug Class to 2021 & 2031
Figure 20: North America Market Analysis by Indication to 2021 & 2031
Figure 21: North America Market Analysis by Distribution Channel to 2021 & 2031
Figure 22: Latin America Market Size (US$ Mn) Analysis, 2016 to 2020
Figure 23: Latin America Market Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 24: Latin America Market Analysis by Country to 2021 & 2031
Figure 25: Latin America Market Analysis by Drug Class to 2021 & 2031
Figure 26: Latin America Market Analysis by Indication to 2021 & 2031
Figure 27: Latin America Market Analysis by Distribution Channel to 2021 & 2031
Figure 28: Europe Market Size (US$ Mn) Analysis, 2016 to 2020
Figure 29: Europe Market Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 30: Europe Market Analysis by Country to 2021 & 2031
Figure 31: Europe Market Analysis by Drug Class to 2021 & 2031
Figure 32: Europe Market Analysis by Indication to 2021 & 2031
Figure 33: Europe Market Analysis by Distribution Channel to 2021 & 2031
Figure 34: South Asia Market Size (US$ Mn) Analysis, 2016 to 2020
Figure 35: South Asia Market Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 36: South Asia Market Analysis by Country to 2021 & 2031
Figure 37: South Asia Market Analysis by Drug Class to 2021 & 2031
Figure 38: South Asia Market Analysis by Indication to 2021 & 2031
Figure 39: South Asia Market Analysis by Distribution Channel to 2021 & 2031
Figure 40: East Asia Market Size (US$ Mn) Analysis, 2016 to 2020
Figure 41: East Asia Market Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 42: East Asia Market Analysis by Country to 2021 & 2031
Figure 43: East Asia Market Analysis by Drug Class to 2021 & 2031
Figure 44: East Asia Market Analysis by Indication to 2021 & 2031
Figure 45: East Asia Market Analysis by Distribution Channel to 2021 & 2031
Figure 46: Oceania Market Size (US$ Mn) Analysis, 2016 to 2020
Figure 47: Oceania Market Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 48: Oceania Market Analysis by Country to 2021 & 2031
Figure 49: Oceania Market Analysis by Drug Class to 2021 & 2031
Figure 50: Oceania Market Analysis by Indication to 2021 & 2031
Figure 51: Oceania Market Analysis by Distribution Channel to 2021 & 2031
Figure 52: MEA Market Size (US$ Mn) Analysis, 2016 to 2020
Figure 53: MEA Market Size (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 54: MEA Market Analysis by Country to 2021 & 2031
Figure 55: MEA Market Analysis by Drug Class to 2021 & 2031
Figure 56: MEA Market Analysis by Indication to 2021 & 2031
Figure 57: MEA Market Analysis by Distribution Channel to 2021 & 2031
Figure 58: U.S. Market Value Proportion Analysis (2020)
Figure 59: Global Vs. U.S. Growth Comparison
Figure 60: U.S. Market Share Analysis (%), by Product
Figure 61: U.S. Market Share Analysis (%), by Indication
Figure 62: U.S. Market Share Analysis (%), by Distribution Channel
Figure 63: Canada Market Value Proportion Analysis (2020)
Figure 64: Global Vs. Canada Growth Comparison
Figure 65: Canada Market Share Analysis (%), by Product
Figure 66: Canada Market Share Analysis (%), by Indication
Figure 67: Canada Market Share Analysis (%), by Distribution Channel
Figure 68: Brazil Market Value Proportion Analysis (2020)
Figure 69: Global Vs. Brazil Growth Comparison
Figure 70: Brazil Market Share Analysis (%), by Product
Figure 71: Brazil Market Share Analysis (%), by Indication
Figure 72: Brazil Market Share Analysis (%), by Distribution Channel
Figure 73: Mexico Market Value Proportion Analysis (2020)
Figure 74: Global Vs. Mexico Growth Comparison
Figure 75: Mexico Market Share Analysis (%), by Product
Figure 76: Mexico Market Share Analysis (%), by Indication
Figure 77: Mexico Market Share Analysis (%), by Distribution Channel
Figure 78: Germany Market Value Proportion Analysis (2020)
Figure 79: Global Vs. Germany Growth Comparison
Figure 80: Germany Market Share Analysis (%), by Product
Figure 81: Germany Market Share Analysis (%), by Indication
Figure 82: Germany Market Share Analysis (%), by Distribution Channel
Figure 83: Italy Market Value Proportion Analysis (2020)
Figure 84: Global Vs. Italy Growth Comparison
Figure 85: Italy Market Share Analysis (%), by Product
Figure 86: Italy Market Share Analysis (%), by Indication
Figure 87: Italy Market Share Analysis (%), by Distribution Channel
Figure 88: France Market Value Proportion Analysis (2020)
Figure 89: Global Vs. France Growth Comparison
Figure 90: France Market Share Analysis (%), by Product
Figure 91: France Market Share Analysis (%), by Indication
Figure 92: France Market Share Analysis (%), by Distribution Channel
Figure 93: U.K Market Value Proportion Analysis (2020)
Figure 94: Global Vs. U.K Growth Comparison
Figure 95: U.K Market Share Analysis (%), by Product
Figure 96: U.K Market Share Analysis (%), by Indication
Figure 97: U.K Market Share Analysis (%), by Distribution Channel
Figure 98: Spain Market Value Proportion Analysis (2020)
Figure 99: Global Vs. Spain Growth Comparison
Figure 100: Spain Market Share Analysis (%), by Product
Figure 101: Spain Market Share Analysis (%), by Indication
Figure 102: Spain Market Share Analysis (%), by Distribution Channel
Figure 103: BENULUX Market Value Proportion Analysis (2020)
Figure 104: Global Vs. BENULUX Growth Comparison
Figure 105: BENULUX Market Share Analysis (%), by Product
Figure 106: BENULUX Market Share Analysis (%), by Indication
Figure 107: BENULUX Market Share Analysis (%), by Distribution Channel
Figure 108: Russia Market Value Proportion Analysis (2020)
Figure 109: Global Vs. Russia Growth Comparison
Figure 110: Russia Market Share Analysis (%), by Product
Figure 111: Russia Market Share Analysis (%), by Indication
Figure 112: Russia Market Share Analysis (%), by Distribution Channel
Figure 113: India Market Value Proportion Analysis (2020)
Figure 114: Global Vs. India Growth Comparison
Figure 115: India Market Share Analysis (%), by Product
Figure 116: India Market Share Analysis (%), by Indication
Figure 117: India Market Share Analysis (%), by Distribution Channel
Figure 118: Thailand Market Value Proportion Analysis (2020)
Figure 119: Global Vs. Thailand Growth Comparison
Figure 120: Thailand Market Share Analysis (%), by Product
Figure 121: Thailand Market Share Analysis (%), by Indication
Figure 122: Thailand Market Share Analysis (%), by Distribution Channel
Figure 123: Malaysia Market Value Proportion Analysis (2020)
Figure 124: Global Vs. Malaysia Growth Comparison
Figure 125: Malaysia Market Share Analysis (%), by Product
Figure 126: Malaysia Market Share Analysis (%), by Indication
Figure 127: Malaysia Market Share Analysis (%), by Distribution Channel
Figure 128: Indonesia Market Value Proportion Analysis (2020)
Figure 129: Global Vs. Indonesia Growth Comparison
Figure 130: Indonesia Market Share Analysis (%), by Product
Figure 131: Indonesia Market Share Analysis (%), by Indication
Figure 132: Indonesia Market Share Analysis (%), by Distribution Channel
Figure 133: China Market Value Proportion Analysis (2020)
Figure 134: Global Vs. China Growth Comparison
Figure 135: China Market Share Analysis (%), by Product
Figure 136: China Market Share Analysis (%), by Indication
Figure 137: China Market Share Analysis (%), by Distribution Channel
Figure 138: Japan Market Value Proportion Analysis (2020)
Figure 139: Global Vs. Japan Growth Comparison
Figure 140: Japan Market Share Analysis (%), by Product
Figure 141: Japan Market Share Analysis (%), by Indication
Figure 142: Japan Market Share Analysis (%), by Distribution Channel
Figure 143: South Korea Market Value Proportion Analysis (2020)
Figure 144: Global Vs. South Korea Growth Comparison
Figure 145: South Korea Market Share Analysis (%), by Product
Figure 146: South Korea Market Share Analysis (%), by Indication
Figure 147: South Korea Market Share Analysis (%), by Distribution Channel
Figure 148: Australia Market Value Proportion Analysis (2020)
Figure 149: Global Vs. Australia Growth Comparison
Figure 150: Australia Market Share Analysis (%), by Product
Figure 151: Australia Market Share Analysis (%), by Indication
Figure 152: Australia Market Share Analysis (%), by Distribution Channel
Figure 153: New Zealand Market Value Proportion Analysis (2020)
Figure 154: Global Vs. New Zealand Growth Comparison
Figure 155: New Zealand Market Share Analysis (%), by Product
Figure 156: New Zealand Market Share Analysis (%), by Indication
Figure 157: New Zealand Market Share Analysis (%), by Distribution Channel
Figure 158: GCC Countries Market Value Proportion Analysis (2020)
Figure 159: Global Vs. GCC Countries Growth Comparison
Figure 160: GCC Countries Market Share Analysis (%), by Product
Figure 161: GCC Countries Market Share Analysis (%), by Indication
Figure 162: GCC Countries Market Share Analysis (%), by Distribution Channel
Figure 163: Turkey Market Value Proportion Analysis (2020)
Figure 164: Global Vs. Turkey Growth Comparison
Figure 165: Turkey Market Share Analysis (%), by Product
Figure 166: Turkey Market Share Analysis (%), by Indication
Figure 167: Turkey Market Share Analysis (%), by Distribution Channel
Figure 168: Northern Africa Market Value Proportion Analysis (2020)
Figure 169: Global Vs. Northern Africa Growth Comparison
Figure 170: Northern Africa Market Share Analysis (%), by Product
Figure 171: Northern Africa Market Share Analysis (%), by Indication
Figure 172: Northern Africa Market Share Analysis (%), by Distribution Channel
Figure 173: South Africa Market Value Proportion Analysis (2020)
Figure 174: Global Vs. South Africa Growth Comparison
Figure 175: South Africa Market Share Analysis (%), by Product
Figure 176: South Africa Market Share Analysis (%), by Indication
Figure 177: South Africa Market Share Analysis (%), by Distribution Channel
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the urinary tract infection treatment market currently worth?
The global urinary tract infection treatment market was worth US$ 10.3 Bn in.
What is be demand outlook for urinary tract infection treatment?
The market is expected to reach US$ 12.9 Bn by the end of 2031, expanding at a CAGR of 2.1%.
At what CAGR did the UTI market grow over the past 5 years?
The market for urinary tract infection treatment progressed at 1.5% CAGR from 2016 to 2020.
What are the key trends related to urinary tract infection treatment?
Highly saturated market, increasing per capita consumption of antibiotics, rise in complicated UTI (cUTI) cases, and acquisitions & regional expansion are key trends in this space.
Which are the top 5 countries driving demand for urinary tract infection treatment?
The U.S., Japan, China, India, and France are the top 5 countries driving demand for UTI treatment.
What is the outlook for the North America UTI market?
North America is a key market for urinary tract infection treatment, with the U.S. expected to account for 91.4% market share.
At what percentage is demand for urinary tract infection treatment expected to register growth in Europe?
Europe UTI market growth is projected at 2.2% CAGR through 2031.
Who are the leading urinary tract infection treatment providers?
Leading market players are Bayer AG, GlaxoSmithKline Pharmaceuticals Ltd., Pfizer, Allergan Plc, Almirall SA, Bristol-Myers Squibb, and Merck & Co., Inc.
What are the key market statistics for UTI treatment in South Korea and Japan?
The South Korea market is expected to exhibit 1.7% CAGR, while Japan is set to experience 2% CAGR, over the decade.
Urinary Tract Infection Treatment Market